Adage Capital Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Adage Capital Partners’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-408,901	Closed	-$3.35M	–	700
2017 Q3	$3.35M	Sell	408,901 -50,000	-11%	-$312K	0.01%	651
2017 Q2	$2.06M	Sell	458,901 -25,000	-5%	-$131K	0.01%	666
2017 Q1	$2.67M	Sell	483,901 -50,000	-9%	-$219K	0.01%	655
2016 Q4	$2.16M	Sell	533,901 -623,148	-54%	-$2.99M	0.01%	648
2016 Q3	$8.16M	Sell	1,157,049 -392,951	-25%	-$3M	0.02%	552
2016 Q2	$12.6M	Buy	1,550,000 +400,000	+35%	+$3.77M	0.03%	471
2016 Q1	$9.35M	Buy	1,150,000 +300,000	+35%	+$2.45M	0.03%	534
2015 Q4	$10.3M	Buy	850,000 +500,000	+143%	+$4.9M	0.03%	519
2015 Q3	$4.19M	Buy	350,000 +50,000	+17%	+$706K	0.01%	627
2015 Q2	$5.5M	Buy	+300,000	New	+$5.15M	0.01%	626

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Adage Capital Partners's ADAP Position: Q4 2017 in Review

Adage Capital Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2017, closing a stake of 408,901 shares — an estimated $3.35M sold.

Adage Capital Partners first reported a position in ADAP in Q2 2015 and held it in 10 quarters. The position peaked at $12.6M in Q2 2016. 71 funds tracked by Wall St. Rank hold ADAP as of Q4 2017.

Adage Capital Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
Adage Capital Partners sold 408,901 Adaptimmune Therapeutics shares in Q4 2017, an estimated $3.35M.
Adage Capital Partners first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 10 quarters.
Adage Capital Partners's Adaptimmune Therapeutics position peaked at $12.6M in Q2 2016.
71 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2017.

Based on Adage Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.